PubRank

Judith A M Wessels

Author PubWeight™ 22.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012 1.65
2 Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009 1.60
3 Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2010 1.57
4 Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011 1.07
5 Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007 1.04
6 Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002 0.99
7 Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford) 2009 0.98
8 A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2011 0.91
9 Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009 0.88
10 Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics 2012 0.82
11 Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact 2012 0.82
12 Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest New Drugs 2010 0.81
13 Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. Int J Cardiol 2012 0.80
14 Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics 2010 0.80
15 Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease. Eur J Clin Pharmacol 2009 0.78
16 CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat 2013 0.78
17 Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle. Pharmacogenomics 2010 0.77
18 Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenet Genomics 2013 0.77
19 Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discov Today 2009 0.76
20 Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians. Int J Biol Markers 2012 0.76
21 Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment. Pharmacogenet Genomics 2011 0.76
22 Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose. Pharmacogenomics 2012 0.76
23 Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics 2012 0.75
24 Genetic markers of treatment response in rheumatoid arthritis. Curr Rheumatol Rep 2006 0.75
25 SNPs and haplotypes in DPYD and outcome of capecitabine--Letter. Clin Cancer Res 2011 0.75
26 Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol 2011 0.75